Published by Erik Greb on August 2, 2010
under Biotech, Europe News, Manufacturing, North America News, Regulation, Trends
In the current economic slump, generic versions of branded drugs have become a bigger thorn in innovators’ sides than before. To safeguard their profits for just a bit longer, many companies have paid generic-drug manufacturers to delay the introduction of their products to the market. US and European authorities have called these arrangements anticompetitive, though, and events on Capitol Hill last week indicate that they might not be tolerated much longer. Read more »
Published by Patricia Van Arnum on November 24, 2009
under Regulation
The US Senate’s vote this past weekend to proceed with debate on a legislative proposal for healthcare reform portends—what by all accounts—promises to be yet another rigorous round of policy and political opinion. A Google search for the past week alone shows that almost 500,000 blogs (459,049 at the time of posting of this blog) have been posted in response to the Senate’s action to move forward with considering healthcare reform. In the swirl of this public opinion, where does the pharmaceutical industry stand? Read more »
Published by Erik Greb on November 9, 2009
under Biotech, Manufacturing, North America News, Regulation, Trends
After much ado, the US House of Representatives passed a healthcare-reform bill this weekend. Drugmakers and commentators are understandably eager to parse the bill to find out what it would mean for the pharmaceutical and biopharmaceutical industries. So what’s the verdict? Read more »
Published by Erik Greb on July 13, 2009
under Biotech, Manufacturing, North America News, Regulation
Last week, the Biotechnology Industry Organization (BIO) and the Generic Pharmaceutical Association (GPhA) released dueling statements about the proposal to establish an approval pathway for follow-on biologics that the Senate Committee on Health, Education, Labor, and Pensions (HELP) is considering. Are the two antagonists advancing the debate? Read more »
Published by Erik Greb on July 6, 2009
under Biotech, Manufacturing, North America News, Regulation, Trends
Congress has taken up the Obama administration’s goal of making healthcare more affordable by introducing various strategies for reducing the cost of prescription drugs. But the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization (BIO) have resisted several of Congress’s initiatives, and cost control has been elusive so far. Read more »
Published by Erik Greb on June 22, 2009
under North America News, Regulation, Trends
This month, lawmakers such as Senator Kent Conrad (D-ND) and Senator Edward Kennedy (D-MA) have introduced a flurry of healthcare-reform bills that provide for comparative-effectiveness (CE) research. Supporters of CE research say that it could cut unnecessary costs by identifying the treatments that produce the best results. Federal and state governments’ share of the national healthcare bill could consequently be lighter, yet critics fear that promoting CE research could give the government too much power over treatment. Read more »
Published by Erik Greb on June 8, 2009
under Manufacturing, North America News, Regulation, Trends
President Obama’s plan for lowering the cost of healthcare relies partly on ensuring that affordable generic drugs are available to patients. This strategy is not likely to be palatable to innovator companies, who have tried various ways of delaying generic drugs’ introduction to the market. Read more »
Published by Erik Greb on May 11, 2009
under Analytics, Manufacturing, North America News, Products, Regulation, Trends
Perhaps out of embarrassment at the stream of incidents involving contaminated products, the US Food and Drug Administration has requested the largest budget increase in its history. The agency intends to use part of the funds for its proposed Safer Medical Products initiative, which will scrutinize domestic and imported drugs. Will it use the money wisely? Read more »
Published by Erik Greb on January 5, 2009
under Manufacturing, North America News, Regulation
Now is the time when the ambitious among us decide how we’re going to improve ourselves during the new year. The pharmaceutical industry is starting 2009 with an effort to reassure the public that its interactions with doctors are on the up and up. Read more »
Published by Erik Greb on October 27, 2008
under Manufacturing, North America News, Regulation
The 2008 election is only a week away, and much of the public discussion focuses on the presidential race between Obama and McCain. It’s easy to lose sight of the fact that voters will also choose their US senators and representatives. This point is not lost on the Pharmaceutical Research and Manufacturers of America (PhRMA). Read more »